ERBB2 and cancer: Twenty-five percent of lesions were categorized as triple-negative breast cancers, (TNBC) (13/52), 50% as HER2-positive tumors (26/52), and the remaining 25% as ER-positive/HER negative cancers (13/52), the majority of them having node involvement (10/13).